Shots:

• Morphic to receive upfront- $725M milestones- and royalties on WW sales of products. Janssen to get exclusive option to license integrin therapies post IND submission and will fund the clinical trials
• If the option is exercised- Janssen to get exclusive WW development and commercialization rights of the products
• Morphic’s Integrins are receptors present on human cells responsible for cell survival- cell cycle progression- cell differentiation- and cell migration focusing on fibrosis- autoimmune diseases- and immuno-oncology

Ref: Morphic Therapeutics | Image: Janssen